Cargando…

Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial

BACKGROUND: Glioblastoma (GBM), the most lethal primary brain tumor, has limited treatment options upon recurrence after chemoradiation and bevacizumab. TRC105 (carotuximab), a chimeric anti-endoglin (CD105) antibody, inhibits angiogenesis and potentiates activity of VEGF inhibitor bevacizumab in pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ahluwalia, Manmeet S., Rogers, Lisa R., Chaudhary, Rekha, Newton, Herbert, Ozair, Ahmad, Khosla, Atulya A., Nixon, Andrew B., Adams, Bonne J., Seon, Ben K., Peereboom, David M., Theuer, Charles P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10491825/ https://www.ncbi.nlm.nih.gov/pubmed/37684373 http://dx.doi.org/10.1038/s43856-023-00347-0

Ejemplares similares

Effects of the combination of TRC105 and bevacizumab on endothelial cell biology
por: Liu, Yingmiao, et al.
Publicado: (2014)

Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer
por: Liu, Yingmiao, et al.
Publicado: (2014)

Monoclonal anti-endoglin antibody TRC105 (carotuximab) prevents hypercholesterolemia and hyperglycemia-induced endothelial dysfunction in human aortic endothelial cells
por: Tripska, Katarina, et al.
Publicado: (2022)

Therapeutic effect of TRC105 and decitabine combination in AML xenografts
por: Baik, June, et al.
Publicado: (2020)

Novel Therapeutic Approaches in Neoplastic Meningitis
por: Khosla, Atulya Aman, et al.
Publicado: (2022)

Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance)
por: Galanis, Evanthia, et al.
Publicado: (2022)

An adaptive population enrichment phase III trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS trial)
por: Mehta, C R, et al.
Publicado: (2019)

Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial
por: Jones, Robin L., et al.
Publicado: (2022)

In Vivo Tumor Vasculature Targeted PET/NIRF Imaging with TRC105(Fab)-Conjugated, Dual-Labeled Mesoporous Silica Nanoparticles
por: Chen, Feng, et al.
Publicado: (2014)

Expression of endoglin (CD105) in cervical cancer
por: Zijlmans, H J, et al.
Publicado: (2009)

Antibody-directed coupling of endoglin and MMP-14 is a key mechanism for endoglin shedding and deregulation of TGF-β signaling
por: Kumar, S, et al.
Publicado: (2014)

First- versus Third-Generation EGFR Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases
por: Tatineni, Vineeth, et al.
Publicado: (2023)

Evaluation of Endoglin (CD105) expression in pediatric rhabdomyosarcoma
por: Di Paolo, Virginia, et al.
Publicado: (2018)

CD105 (Endoglin) as negative prognostic factor in AML
por: Kauer, Joseph, et al.
Publicado: (2019)

Combination of EGFR-Directed Tyrosine Kinase Inhibitors (EGFR-TKI) with Radiotherapy in Brain Metastases from Non-Small Cell Lung Cancer: A 2010–2019 Retrospective Cohort Study
por: Tatineni, Vineeth, et al.
Publicado: (2023)

DNA Methylation and Histone Modification in Low-Grade Gliomas: Current Understanding and Potential Clinical Targets
por: Ozair, Ahmad, et al.
Publicado: (2023)

Identification of CD105 (endoglin) as novel risk marker in CLL
por: Greiner, Sarah M., et al.
Publicado: (2022)

Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges
por: Rahmathulla, Gazanfar, et al.
Publicado: (2013)

Effect of the monoclonal antibody TRC105 in combination with Sunitinib on renal tumor derived endothelial cells
por: Brossa, Alessia, et al.
Publicado: (2018)

Study of expression of endoglin (CD105) in oral squamous cell carcinoma
por: Mahapatra, Niva, et al.
Publicado: (2021)

Role of Endoglin (CD105) in the Progression of Hepatocellular Carcinoma and Anti-Angiogenic Therapy
por: Kasprzak, Aldona, et al.
Publicado: (2018)

Endoglin (CD105) and VEGF as potential angiogenic and dissemination markers for colorectal cancer
por: Nogués, Ana, et al.
Publicado: (2020)

TRC: Mission Accomplished
por: Hood, Ernie
Publicado: (2007)

Particular distribution and expression pattern of endoglin (CD105) in the liver of patients with hepatocellular carcinoma
por: Yu, Decai, et al.
Publicado: (2007)

Endoglin (CD105) expression in ovarian serous carcinoma effusions is related to chemotherapy status
por: Bock, Annika J., et al.
Publicado: (2011)

ENDOGLIN/CD105 is expressed in KIT positive cells in the gut and in gastrointestinal stromal tumours
por: Gromova, Petra, et al.
Publicado: (2012)

Continuous endoglin (CD105) overexpression disrupts angiogenesis and facilitates tumor cell metastasis
por: Ollauri-Ibáñez, Claudia, et al.
Publicado: (2020)

Hot and Cold Tumors: Is Endoglin (CD105) a Potential Target for Vessel Normalization?
por: Ollauri-Ibáñez, Claudia, et al.
Publicado: (2021)

Endoglin/CD105-Based Imaging of Cancer and Cardiovascular Diseases: A Systematic Review
por: Sier, Vincent Q., et al.
Publicado: (2021)

Horoscopic role of CD105 (Endoglin) in progression of oral lichen planus: An immunohistochemical study
por: Parvathala, Poornima, et al.
Publicado: (2021)

Endoglin (CD105) and proliferation index in recurrent glioblastoma treated with anti-angiogenic therapy
por: Bastos, António G. P., et al.
Publicado: (2022)

Effect of TRC and F/TRC Strengthening on the Cracking Behaviour of RC Beams in Bending
por: Rossi, Edoardo, et al.
Publicado: (2021)

Reinduction of Bevacizumab in Combination with Pegylated Liposomal Doxorubicin in a Patient with Recurrent Glioblastoma Multiforme Who Progressed on Bevacizumab/Irinotecan
por: Almubarak, Mohammed, et al.
Publicado: (2008)

Bevacizumab for glioblastoma
por: Narita, Yoshitaka
Publicado: (2015)

Intravitreal bevacizumab
por: Khamar, Bakulesh M
Publicado: (2018)

A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
por: Hummel, Matthew, et al.
Publicado: (2021)

Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer
por: Fonsatti, Ester, et al.
Publicado: (2004)

PROGNOSTIC ROLE OF CD44 EXPRESSION AND NEOVASCULARIZATION DETERMINED BY ENDOGLIN (CD105) IN GLIOBLASTOMA PATIENTS
por: Mihić, Josip, et al.
Publicado: (2019)

Endoglin (CD105) as a putative prognostic biomarker for colorectal cancer: a systematic review
por: Sur, Daniel, et al.
Publicado: (2022)

Update on the Management of Brain Metastasis
por: Singh, Karanvir, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_evoddsg5okis8dg1u3d9skcml6